Nalaganje...
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a monoclonal antibody (mAb) that binds to CD20 on the surface of B cells, and belimumab, a mAb that binds and neutr...
Shranjeno v:
| izdano v: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338653/ https://ncbi.nlm.nih.gov/pubmed/32695790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.00303 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|